Rotation thromboelastometry (ROTEM) enables improved outcomes in the pediatric trauma population

Qin Deng¹, Fabao Hao¹,², Yongming Wang¹,²,* and Chunbao Guo¹,³,*

Abstract

Objective: We evaluated the role of rotation thromboelastometry (ROTEM) in managing acute traumatic coagulopathy in pediatric patients with trauma.

Methods: A retrospective cohort of pediatric patients with trauma from six institutes was studied during a 10-year period from 2007 to 2017. The associations between ROTEM-guided, goal-directed coagulation therapy and clinical outcomes were determined.

Results: Three hundred thirty-two pediatric patients (age < 15 years) who were treated with ROTEM-guided, goal-directed coagulation therapy were matched to 332 control pediatric patients with conventional plasmatic coagulation tests. The ROTEM protocol was associated with a significant reduction in the interval for admission to acute traumatic coagulopathy treatment, less plasma transfusions in the first 24 hours of admission, and a favorable coagulopathy recovery. Furthermore, the median number of total hospital days was significantly shorter for patients who had the ROTEM protocol than for control patients.

Conclusions: There are significant favorable outcomes, including rapid acute traumatic coagulopathy treatment and a lower 24-hour blood product requirement, following ROTEM-guided, goal-directed coagulation therapy among pediatric patients with blunt trauma.

¹Department of Pediatric General Surgery and Liver Transplantation, Children's Hospital, Chongqing Medical University, Chongqing, China
²Department of Neonatology, Children's Hospital, Chongqing Medical University, Chongqing, China
³Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital, Chongqing Medical University, Chongqing, China

*These authors contributed equally to this work.

Corresponding author:
Chunbao Guo, Department of Pediatric General Surgery and Liver Transplantation, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2nd Rd., Chongqing, 400014, China.
Email: guochunbao@foxmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

In patients with severe trauma, significant blood loss is frequently associated with coagulopathy, which causes approximately 40% of early mortality. Therefore, this problem is a major challenge in trauma centers worldwide. Accurate and timely detection of the hemostatic potential to prevent and correct life-threatening bleeding is of clinical importance for optimizing prompt intervention of coagulopathy.

Currently, management of coagulopathy for pediatric patients mainly relies on conventional laboratory coagulation tests, including the prothrombin time (PT), activated partial thromboplastin time (APTT), and plasma fibrinogen levels. Pathological values in standard laboratory coagulation tests are rarely associated with acute, clinically relevant bleeding. Additionally, determining the PT and APTT is too time-consuming to provide prompt results, and might delay prompt hemostatic therapy. In contrast to plasmatic coagulation tests, viscoelastic assays, including thromboelastometry or thromboelastography, offer information not only for initiation of coagulation, but also for the clot formation process and clot stability. Therefore, these assays closely reflect the in vivo situation. Further, the first results for point-of-care methods (thromboelastography or thromboelastometry) are available within 10 minutes of initiating the test. Therefore, these results can provide a more rapid diagnosis than laboratory tests. However, only a few studies that included a small number of patients have reported viscoelastic measurements in trauma patients. Studies focusing on the pediatric patient population, who might show specific pathology, are lacking.

In most trauma centers, a large amount of fresh frozen plasma (FFP) is part of the treatment protocol. FFP is associated with delayed correction of acute traumatic coagulopathy (ATC) and an increased incidence of infection, sepsis, acute lung injury, and multiorgan failure. One advantage of coagulation factor concentrates is that they are immediately available, and thus eliminate time delays associated with preparation of allogeneic blood products for transfusion. Another advantage is that coagulation factors contain high concentrations of the factor(s) of interest, thus enabling rapid restoration of hemostasis without volume expansion. This reduces adverse events of allogeneic transfusion.

Since 2007, rotation thromboelastometry (ROTEM®, Pentapharm, Munich, Germany) has been performed in our institute as a point-of-care monitoring tool for monitoring and guiding goal-directed therapy of specific coagulation aberrations in pediatric patients. This study aimed to investigate and evaluate the potential usefulness of this technology for sufficiently restoring hemostasis and reducing blood product use in pediatric patients with major trauma.

Methods

Study population

This was a multicenter, retrospective cohort study for pediatric patients with a blunt
injury at six level 1 pediatric trauma centers, including Sanxian Hospital, Jinan Children’s Hospital, Qingdao Municipal Hospital, Yongchuan Hospital, Linyi Municipal Hospital, and Children’s Hospital of Chongqing Medical University. Patients who were admitted to one of these six institutions during the 10 years from 2007 to 2017 were included. Among the included trauma centers, comparable clinical routine guidelines were implemented to minimize variations in trauma care, including coagulation management, infection management, and restrictive transfusion. Eligible inclusion for this retrospective cohort study included age <15 years; blunt injury to any region of the body excluding the brain; base deficit of ≥2 mmol/L of hemoglobin concentrations; and an Abbreviated Injury Scale (AIS) score of ≥2. Exclusion criteria were as follows: isolated traumatic brain injury; penetrating injuries; patients who were admitted to the study hospital later than 12 hours after trauma, patients who had pre-existing bleeding diathesis; and patients who received intravenous fluids before admission. To eliminate survivor bias, patients who died within 12 hours of admission and admission to the intensive care unit were excluded from analysis of transfusion outcomes. The study protocol was approved by the ethics committee of each institute that was involved. The need for written informed consent was waived because all of the patients were treated according to routine institutional treatment guidelines. Demographic data, laboratory data, trauma scores, and outcomes data were obtained from the electronic database.

To aid the goal-directed treatment algorithms, viscoelastic assays was performed using ROTEM beginning from 8 February 2013 in our institution, from 9 January 2015 in Jinan Children’s Hospital, and from 11 January 2013 in Qingdao Municipal Hospital. Samples were processed immediately following collecting blood at 37°C on a ROTEM delta instrument (Pentapharm GmbH, Munich, Germany). The ROTEM parameters of clotting time, alpha angle (\(\alpha\)), clot formation time, clot amplitude at 5 minutes, and maximum clot firmness (MCF) were reported for each sample analyzed. Additional ROTEM tests were ordered on the basis of clinical assessment of bleeding to evaluate the response profile for coagulation parameters during treatment.

Transfusion of blood components and administration of coagulation factor concentrates

Among the included institutes, the general approach to coagulation management of trauma patients included FFP and cryoprecipitate administered as first-line hemostatic therapy in Chongqing, Qingdao and Linyi, whereas Yongchuan used fibrinogen concentrates. The trigger for fibrinogen administration differed between centers, with a fibrinogen level \(<150\) to \(200\) mg/dL. Platelet concentrate and red blood cells (RBCs) were used as necessary.

For the protocol of ROTEM-guided, goal-directed coagulation management, prothrombin complex concentrate (PCC) or fibrinogen concentrate were used first for immediate treatment until FFP was available according to deficiency detected with viscoelastic testing. Usual thresholds for PCC were an extrinsically activated thromboelastometric test clotting time of >90 s and/or an international normalized ratio (INR) >1.5 as dosages of 25 units/kg, and PCC was repeated as necessary. Fibrinogen concentrate was used to correct low fibrinogen concentrations and/or poor fibrin polymerization (fibrinogen concentrations \(<150–200\) mg/dL = extrinsically activated thromboelastometric test with cytochalasin D [FIBTEM] MCF \(<7\) mm) at dosages of 25 to 50 mg/kg body weight.\(^1\) The platelet concentrate was recommended to increase firmness of the
fibrin-based clot for platelet counts < 50 × 10^9/L and/or poor clot firmness (FIBTEM MCF ≤10–12 mm) because fibrinogen could not fully compensate for decreased platelet levels. The target hemoglobin concentration levels should be > 8 to 9 g dL in actively bleeding trauma patients. Tranexamic acid was a principal component in the coagulation management protocols of all included institutes.

Data collection

Computerized medical records were collected and reviewed retrospectively. We collected information on the patients’ demographics, type and injury severity scale (ISS), time elapsed between trauma and hospital admission, vital signs, standard plasmatic coagulation tests, blood cell count, lactate levels, and base excess at admission, as well as 24-hour transfused blood components, 24-hour dosage of coagulation factors, and 24-hour amount and type of intravenous fluids administered. We also evaluated the AIS, which quantifies injuries from a score of 1 (minor injury) to 6 (non-survivable) in various body regions. A patient’s ISS score was calculated by summing the squares of the three highest AIS scores in three different body regions (values ranged from 1 to 75). The primary outcomes of interest were the time to coagulation management and amount of RBC transfusion. The time to coagulation management was defined as the time from arrival at trauma centers to the time of the first dosage of PCC, fibrinogen concentrate, or blood product use. The secondary outcomes were the proportion of patients with normalized coagulopathy within 24 hours and hemorrhage-related mortality within 24 hours. Other outcomes included 24-hour blood product use (RBCs, plasma, platelets, and cryoprecipitate) and hospital length of stay.

Propensity score matching

Propensity score analyses were performed using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA) or R software 3.1.2 (www.r-project.org), and the MatchIt package (www.r-project.org). There was an imbalance in the number of subjects between groups and those receiving goal-directed coagulation therapy via ROTEM protocol were not randomly assigned. Therefore, propensity matching was performed using a 1:1 ratio nearest neighbor algorithm to minimize the effect of potential confounders on selection bias in baseline characteristics. The selected covariates entered into the propensity model included sex, admission INR, admission hemoglobin, initial base deficit, and ISS score. Propensity scores were estimated using a multivariable logistic regression model. A 0.2 caliper width was specified during the matching procedure and matching without replacement was performed on the basis of the estimated propensity score of each patient. Propensity model discrimination and goodness of fit were assessed for the balance of covariates used in propensity score estimation after matching using the C-statistic and the Hosmer–Lemeshow test, respectively.

Statistical analysis

After propensity score matching, the matched ROTEM protocol patients and controls (patients with plasmatic tests) were subjected to statistical comparisons using IBM SPSS Statistics for Windows, version 20.0 (IBM Corp.). Continuous data are presented as mean ± standard deviation or median (minimum, maximum, or 25th and 75th interquartile range [IQR]) unless otherwise indicated. Categorical data are reported as percentages. For univariate comparisons, the Student’s t-test, Shapiro–Wilk test, or Wilcoxon rank sum
(Mann–Whitney U test) was used to compare continuous variables. The $\chi^2$ test or Fisher’s exact test was used to compare categorical variables. A P value of $\leq 0.05$ was considered significant with two-sided tests.

Results

At the time of the analysis, a total of 762 pediatric patients who were suffering from trauma injury were eligible for analysis. Among them, 366 patients received the ROTEM-guided, goal-directed coagulation therapy protocol (ROTEM group). The demographics, clinical characteristics, routine trauma panel values, and admission laboratory parameters are shown in Table 1. Notably, there were no differences in sex, admission platelet levels, base deficit, lactate levels, PT, APTT, and INR at arrival between the ROTEM group and the plasmatic coagulation tests group. There were no significant differences in the ISS score and initial hemoglobin values between the two groups with unmatched patients (Table 1). With propensity score matching, 332 patients with ROTEM-guided, goal-directed coagulation therapy were well matched to 332 patients with plasmatic coagulation tests. After matching, several variables, including unstable hemodynamics, the ISS score, and initial hemoglobin levels, became more comparable after propensity score matching (Table 1).

After blood sampling, standard coagulation measurements were transmitted via

### Table 1. Demographics, injury, and laboratory characteristics of patients before and after PS matching based on ROTEM compared with conventional plasmatic coagulation tests

|                  | ROTEM before PS matching (n = 350) | Plasmatic tests before PS matching (n = 412) | p     | ROTEM after PS matching (n = 332) | Plasmatic tests after PS matching (n = 332) | p     |
|------------------|-------------------------------------|-----------------------------------------------|-------|----------------------------------|-----------------------------------------------|-------|
| Male sex, n (%)  | 138 (39.43)                         | 161 (39.08)                                   | 0.49  | 133 (40.06)                      | 119 (35.84)                                   | 0.15  |
| Weight, kg       | 21.89 ± 9.27                        | 22.31 ± 9.29                                  | 0.53  | 22.28 ± 9.07                     | 22.14 ± 9.39                                  | 0.85  |
| Interval from injury (hours) | 5.53 ± 4.68               | 5.79 ± 3.18                                   | 0.38  | 5.39 ± 3.04                      | 5.74 ± 3.22                                   | 0.16  |
| Fibrinogen (g/L) | 1.57 ± 0.45                         | 1.58 ± 0.46                                   | 0.71  | 1.57 ± 0.45                      | 1.58 ± 0.46                                   | 0.74  |
| Platelet count ($\times 10^9$/L) | 251.70 ± 77.76                     | 256.74 ± 78.79                                | 0.38  | 255.91 ± 75.91                   | 256.91 ± 79.60                                | 0.87  |
| Initial hemoglobin, g/dL | 103.69 ± 16.30                 | 106.52 ± 15.45                                | 0.014 | 104.72 ± 14.96                   | 106.24 ± 14.96                                | 0.19  |
| Lactate on admission, mmol/L | 3.91 ± 1.04                         | 3.82 ± 0.99                                   | 0.21  | 3.84 ± 0.97                      | 3.85 ± 0.99                                   | 0.91  |
| PT (seconds)     | 13.16 ± 2.02                        | 13.04 ± 1.72                                  | 0.36  | 13.07 ± 1.78                     | 13.08 ± 1.78                                  | 0.94  |
| APTT (seconds)   | 27.81 ± 6.83                        | 27.57 ± 5.33                                  | 0.60  | 27.63 ± 6.30                     | 27.74 ± 5.50                                  | 0.81  |
| INR, median (IQR) | 1.09 (1.02, 1.16)                  | 1.08 (1.02, 1.14)                             | 0.75  | 1.09 (1.02, 1.15)                | 1.08 (1.02, 1.14)                             | 0.96  |
| Coagulopathy on admission, n (%) | 74 (21.14)                          | 82 (19.90)                                    | 0.43  | 65 (19.58)                       | 65 (19.58)                                    | 0.50  |
| ISS score, median (IQR) | 11.75 ± 7.58                      | 10.52 ± 6.38                                  | 0.015 | 11.06 ± 6.71                     | 10.59 ± 6.58                                  | 0.36  |
| Admission base deficit $> 6$ mmol/L, n (%) | 73 (20.86)                          | 74 (17.96)                                    | 0.18  | 61 (18.37)                       | 60 (18.07)                                    | 0.50  |
| Unstable hemodynamics, n (%) | 56 (16.00)                          | 49 (11.89)                                    | 0.063 | 43 (12.95)                       | 42 (12.65)                                    | 0.50  |

Data are mean ± standard deviation, median (IQR), or n (%) as indicated. ROTEM: rotational thromboelastometry; PS: propensity score; INR: international normalized ratio; IQR: 25th to 75th interquartile range; ISS: injury severity scale; PT: prothrombin time; APTT: activated partial thromboplastin time.
the hospital electronic record system with a median time of 47.5 minutes (IQR: 38.0–63.0), whereas ROTEM results were available online after 21.5 minutes (IQR: 15.0–28.0) (p < 0.001). Outcomes of the matched trauma population are shown in Table 2. Patients in the ROTEM group were associated with a significant reduction in interval from admission to RBC use (p = 0.015), while the time to the first plasma use was similar between the two groups. Significantly less plasma transfusion overall and in the first 24 hours of admission was observed in patients in the ROTEM group than in patients in the plasmatic coagulation tests group (p = 0.005 and p = 0.021, respectively). RBC transfusion was similar in the two groups. In patients in the ROTEM group, 60 of 332 (18.01%) patients received RBC transfusion (median, 150 mL) compared with 75 of 332 (22.6%) patients in the plasmatic coagulation tests group (median, 200 mL). Plasma was administered to 40 (12.04%) patients in the ROTEM group compared with 65 (19.58%) patients in the plasmatic coagulation tests group (p = 0.005).

Table 2. Outcomes of the matched trauma population who were treated on the basis of ROTEM compared with conventional plasmatic tests

| Characteristic                                      | ROTEM (n = 332) | Plasmatic tests (n = 332) | p value |
|-----------------------------------------------------|-----------------|--------------------------|---------|
| Interval from sampling to results, minutes (IQR)    | 21.50 (15.00–28.00) | 47.50 (38.00–63.00)      | <0.001  |
| 24-hour crystalloid, mL/kg                          | 77.84 ± 26.99   | 81.14 ± 27.79            | 0.12    |
| RBC transfusions, n (%)                             | 60 (18.01)      | 75 (22.6)                | 0.088   |
| Interval from admission to RBC use, minutes         | 88.20 ± 17.23   | 96.00 ± 19.60            | 0.015   |
| 24-hour RBC, mL, median (IQR)                       | 150 (50–500)    | 200 (100–400)            | 0.075   |
| Plasma transfusions, n (%)                          | 40 (12.04)      | 65 (19.58)               | 0.005   |
| Interval from admission to plasma use, minutes      | 134.92 ± 65.36  | 141.09 ± 75.44           | 0.66    |
| 24-hour plasma, mL                                  | 147.50 ± 50.57  | 175.38 ± 96.87           | 0.021   |
| Interval from admission to determining fibrinogen levels or PCC, minutes | 57.50 ± 21.32 | –                        |         |
| Determination of fibrinogen levels or PCC, n (%)    | 65 (19.58)      | 23 (6.93)                | <0.001  |
| Coagulopathy after 24 hours, n (%)                  | 21 (6.33)       | 35 (10.54)               | 0.034   |
| ARDS, n (%)                                         | 3 (0.90)        | 2 (0.60)                 | 0.50    |
| Total number of hospital days                       | 11.22 ± 4.39    | 12.09 ± 5.38             | 0.021   |
| Emergent operation after 12 hours, n (%)            | 10 (3.01)       | 12 (3.61)                | 0.41    |
| Platelet nadir <100 (× 10^9/L), n (%)               | 13 (3.91)       | 9 (2.71)                 | 0.26    |
| Hemoglobin nadir < 8 g/dL, n (%)                    | 9 (2.71)        | 11 (3.31)                | 0.41    |
| Mortality (%)                                       | 1 (0.30)        | 0 (0)                    | 0.50    |

Data are mean ± standard, median (IQR), or n (%) as indicated. ROTEM: rotational thromboelastometry; IQR: interquartile range; RBC: red blood cell; ARDS: acute respiratory distress syndrome; PCC: prothrombin complex concentrate.
After the final therapy step, more favorable recovery of coagulopathy was observed in patients in the ROTEM group than in those in the plasmatic coagulation tests group (p = 0.034). Furthermore, both groups had comparable emergent operations performed. The ROTEM group appeared to receive lower 24-hour crystalloid volume than did the plasmatic coagulation tests group (p = 0.12), although this did not reach statistical significance. The median number of total hospital days was significantly shorter for patients in the ROTEM group compared with patients in the plasmatic coagulation tests group (p = 0.021). The effect of the resuscitative strategy on mortality could not be determined because of its rare occurrence.

**Discussion**

This retrospective cohort study showed a reduction in the time to the first transfusion of blood products after implementation of an ROTEM-guided hemostatic therapy. Furthermore, ROTEM-guided hemostatic therapy of patients with bleeding trauma who used PCC, fibrinogen, or a combination with FFP was associated with a reduced total number of hospital days.

Timely administration of hemostatic therapy is critical for survival. In our study, viscoelastic assays could be obtained within a few minutes, and closely reflected the in vivo situation and enabled differentiated diagnosis of primary underlying pathologies, including hyperfibrinolysis. However, the first dose of fibrinogen concentrate is administered at a median time of 57 minutes, and over half of patients receive the first dose of FFP over 2 hours after availability of plasmatic coagulation tests. Furthermore, typical doses of fibrinogen concentrate and PCC only require less than 10 minutes for intravenous infusion. However, extra time is required for blood group matching, thawing, and warming of FFP before administration (thawing and warming usually take approximately 30 minutes), and one unit of FFP is recommended over a period of 30 minutes for administration.

Acquired coagulopathy for patients with trauma is predominantly characterized by poor fibrinogen polymerization, and consequently poor clot firmness, followed by hyperfibrinolysis and prolonged initiation of coagulation. From a pathophysiological point of view, because of low fibrinogen levels (main protein of interest), transfusing FFP as the first-line treatment is questionable because small quantities of FFP are not effective in correcting coagulopathy. Furthermore, administration of FFP may have a dilutional effect on hematocrit, and unavoidably leads to thrombocytopenia. Thrombocytopenia weakens clot strength and aggravates anemia, thereby leading to an increase in RBC transfusion. Successful use of PCC or fibrinogen concentrate to treat acquired coagulopathy has previously been reported in other settings involving extensive surgery and blood loss (e.g., cardiovascular surgery), albeit in limited numbers of patients. The present study showed that coagulation factor treatment effectively corrected coagulopathy and maintained clot firmness, confirming this notion. Transfusion of FFP, carries the risk of noninfectious side effects, such as immunomodulation and pathogen transmission, transfusion-related lung injury, circulatory overload, and development of bloodstream infection or multiple organ failure. However, these findings were not observed in our study. Our study showed a reduction in RBC transfusion among patients who were treated with fibrinogen concentrate and PCCs (ROTEM group) compared with patients who had plasmatic coagulation tests. The faster cessation of bleeding by fibrinogen concentrate and PCCs and relatively low volume of administration for
Hemodilution might provide an explanation for reduced RBC transfusion.

There is increasing evidence that thromboelastometry might provide a more clinically relevant definition of ATC with a characteristic clot strength parameter to accurately predict the need for blood product transfusion.\textsuperscript{26,27} Several reports have described a reduction in the amount of allogeneic blood product transfusion in patients with trauma or liver transplantation following ROTEM-guided coagulation management algorithms\textsuperscript{28,29} compared with standard laboratory tests. A previous study also suggested that the maximum amplitude of thromboelastography within the first 24 hours was a predictor of transfusion.\textsuperscript{30} Austrian guidelines recommend PCC administration in bleeding patients if clotting time as measured by thromboelastography/thromboelastometry is prolonged.\textsuperscript{31} In the present study, PCC was administered to treat bleeding when the clotting time in the ROTEM assay was prolonged and these patients predominantly showed low fibrinogen concentrations and impaired polymerization.

Fibrinogen/fibrin is critically consumed by the clotting process and is consequently required more than other coagulation factors during perioperative hemorrhage and dilutional coagulopathy.\textsuperscript{32} There is growing evidence that considerably higher fibrinogen levels are necessary to control bleeding. Although a minimum plasma fibrinogen level of 1 g/L was recommended by older guidelines,\textsuperscript{33} our clinical experience with ROTEM assays suggests that profuse bleeding commonly occurs at an FIBTEM MCF of 7 mm. This value corresponds to a fibrinogen concentration of 150 mg/dL. Based on the evidence from this study and other studies, viscoelastic assays appear to be more appropriate than standard coagulation assays for diagnosing and treating ATC in patients with blunt trauma.\textsuperscript{34,35}

The present study has certain limitations that need to be taken into account. Primarily, data were retrospectively collected over a long study interval. In practice, there is no executable guideline, and transfusion therapy was not solely based on laboratory findings, but additionally related to clinical observations. We are inclined to perform ROTEM-guided coagulation management in some patients who are prone to more blood loss, which might be associated with severe coagulopathy, and the patients tend to be transferred into the intensive care unit. Therefore, detecting a significant difference in so many heterogeneous variables in our study might have been difficult.

In conclusion, ROTEM assays reliably detect deficiencies, which can affect timely monitoring and guiding coagulation therapy in patients with severe blunt trauma. Early administration of fibrinogen concentrate and FCC should be predominately used to reduce blood loss in pediatric patients with blunt trauma.

Acknowledgments

We thank Prof. Xianqing Jin for providing technical assistance and for insightful discussions during the preparation of the manuscript. We thank Dr Xiaoyong Zhang at the Wistar Institute, USA, for help with linguistic revision of the manuscript.

Author contributions

Qin Deng designed the study, analyzed the data, and evaluated the manuscript. Fabao Hao performed statistical measurements and analyzed the data. Chunbao Guo analyzed the data and wrote the paper.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

The research was supported by the National Natural Science Foundation of China (Nos:
and the Key Project of the Chongqing Natural Science Foundation (CSTC, 2008BA0021, cstc2012jjA0155).

ORCID iD
Chunbao Guo http://orcid.org/0000-0001-5121-9377

References
1. Rahbar E, Fox EE, del Junco DJ, et al. Early resuscitation intensity as a surrogate for bleeding severity and early mortality in the PROMMTT study. J Trauma Acute Care Surg 2013; 75(1 Suppl 1): S16–S23.
2. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148: 127–136.
3. Brown JB, Cohen MJ, Minei JP, et al. Pretrauma center red blood cell transfusion is associated with reduced mortality and coagulopathy in severely injured patients with blunt trauma. Ann Surg 2015; 261: 997–1005.
4. Brown JB, Sperry JL, Fombona A, et al. Pre-trauma center red blood cell transfusion is associated with improved early outcomes in air medical trauma patients. J Am Coll Surg 2015; 220: 797–808.
5. Brown JB, Cohen MJ, Minei JP, et al. Goal-directed resuscitation in the prehospital setting: a propensity-adjusted analysis. J Trauma Acute Care Surg 2013; 74: 1207–1212.
6. Balvers K, van Dieren S, Baksaas-Aasen K, et al. Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. Br J Surg 2017; 104: 222–229.
7. Sorensen B and Fries D. Emerging treatment strategies for trauma-induced coagulopathy. Br J Surg 2012; 99(Suppl 1): 40–50.
8. Haas T, Spielmann N, Mauch J, et al. Comparison of thromboelastometry (ROTEM®) with standard plasmatic coagulation testing in paediatric surgery. Br J Anaesth 2012; 108: 36–41.
9. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792–797.
10. Mesar T, Larentzakis A, Dzik W, et al. Association between ratio of fresh frozen plasma to red blood cells during massive transfusion and survival among patients without traumatic injury. JAMA Surg 2017; 152: 574–580.
11. Cannon JW, Khan MA, Raja AS, et al. Damage control resuscitation in patients with severe traumatic hemorrhage: a practice management guideline from the Eastern Association for the surgery of trauma. J Trauma Acute Care Surg 2017; 82: 605–617.
12. Joseph B, Aziz H, Pandit V, et al. Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference? World J Surg 2014; 38: 1875–1881.
13. Schöchl H, Nienaber U, Maegle M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15: R83.
14. Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4: e258–e271.
15. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 2009; 66: 358–362.
16. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62: 112–119.
17. Innerhofer P, Westermann I, Tauber H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013; 44: 209–216.
18. Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with...
severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555–562.

19. Kozek-Langenecker S, Sorensen B, Hess JR, et al. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15: R239.

20. Chowdary P, Saayman AG, Paulus U, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125: 69–73.

21. Müller MC, Straat M, Meijers JC, et al. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. J Thromb Haemost 2015; 13: 989–997.

22. Solomon C and Rahe-Meyer N. Fibrinogen concentrate as first-line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100 x 10(9)/L. Blood Transfus 2015; 13: 248–254.

23. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795–802.

24. Schick KS, Fertmann JM, Jauch KW, et al. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care 2009; 13: R191.

25. Sarani B, Dunkman WJ, Dean L, et al. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36: 1114–1118.

26. Hagemo JS, Christiaans SC, Stanworth SJ, et al. Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. Crit Care 2015; 19: 97.

27. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256: 476–486.

28. Theusinger OM, Spahn DR and Ganter MT. Transfusion in trauma: why and how should we change our current practice? Curr Opin Anaesthesiol 2009; 22: 305–312.

29. Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140: 1117–1124.

30. Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008; 64(2 Suppl): S64–S68.

31. Fries D, Innerhofer P, Perger P, et al. [Coagulation management in trauma-related massive bleeding. - recommendations of the task force for coagulation (AGPG) of the Austrian Society of Anesthesiology, Resuscitation and Intensive Care Medicine (OGARI)]. Anesthesiol Intensivmed Notfallmed Schmerzther 2010; 45: 552–561 [in German, English Abstract].

32. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101: 769–773.

33. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102: 785–792.

34. Müller MC, Meijers JC, Vroom MB, et al. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care 2014; 18: R30.

35. Gonzalez E, Moore EE and Moore HB. Management of trauma-induced coagulopathy with thrombelastography. Crit Care Clin 2017; 33: 119–134.